Related Experiment Videos
Myocardial perfusion imaging with technetium-99m-labeled agents
J Maddahi1, H Kiat, D S Berman
1Department of Radiological Sciences, UCLA School of Medicine 90024-1721.
The American Journal of Cardiology
|May 21, 1991
Summary
New technetium-99m (99mTc) agents, Tc-sestamibi and Tc-teboroxime, offer improved myocardial perfusion imaging. These agents show comparable diagnostic accuracy to Thallium-201 (201Tl) and are poised to replace it in many clinical applications.
Area of Science:
- Nuclear Medicine
- Cardiovascular Imaging
- Radiopharmaceutical Development
Background:
- Thallium-201 (201Tl) has limitations for myocardial perfusion imaging due to low-energy photons and a long half-life.
- Development of novel radiotracers is crucial for enhancing diagnostic capabilities in cardiology.
Purpose of the Study:
- To introduce and evaluate two new technetium-99m (99mTc) labeled agents, Tc-sestamibi and Tc-teboroxime, for myocardial perfusion imaging.
- To compare the efficacy of these new agents against the established agent, Thallium-201 (201Tl).
Main Methods:
- Clinical trials were conducted using Tc-sestamibi and Tc-teboroxime for myocardial perfusion imaging.
- Assessment of diagnostic accuracy for coronary artery disease, myocardial infarction detection, and ejection fraction calculation.
Main Results:
- Both Tc-sestamibi and Tc-teboroxime demonstrated diagnostic results comparable to 201Tl in detecting coronary artery disease.
- Tc-sestamibi accurately detects myocardial infarction and assesses ventricular ejection fractions; enables same-day rest-stress studies and evaluation of thrombolytic therapy.
- Tc-teboroxime exhibits excellent uptake and rapid myocardial clearance, suitable for serial imaging.
Conclusions:
- Tc-sestamibi and Tc-teboroxime are effective myocardial perfusion imaging agents with performance comparable to 201Tl.
- These new 99mTc agents are now available for clinical use and are expected to supersede 201Tl in many applications.